US FDA approves Johnson & Johnson's drug for immune-average disorder | Mint

The US FDA approved Johnson & Johnson’s drug to treat patients 12 years and older with an immune-average disorder Livemint published 30 Apr 2025, 06:23 PM IST Reuters The US Food and Drug Administration (FDA) approved Johnson & Johnson’s drug to treat patients of 12 years and parent with an immune misdemeanor. Catch all the business news, market news, news reports and latest news updates on Live Mint. Download the Mint News app to get daily market updates. Business NewscienceHealthus FDA approves Johnson & Johnson’s drug for immune-average disorder well published first first: 30 Apr 2025, 06:23 PM IST